diff --git "a/5d250283-8e8b-48d0-9538-6fdee8b4079f.json" "b/5d250283-8e8b-48d0-9538-6fdee8b4079f.json" new file mode 100644--- /dev/null +++ "b/5d250283-8e8b-48d0-9538-6fdee8b4079f.json" @@ -0,0 +1,40 @@ +{ + "interaction_id": "5d250283-8e8b-48d0-9538-6fdee8b4079f", + "search_results": [ + { + "page_name": "PYPD Stock Price | PolyPid Ltd. Stock Quote (U.S.: Nasdaq) | ...", + "page_url": "https://www.marketwatch.com/investing/stock/pypd", + "page_snippet": "PYPD | Complete PolyPid Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3.125 million shares in the IPO... PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. Above average volume.", + "page_result": "\n\n\n\n\n\n PYPD Stock Price | PolyPid Ltd. Stock Quote (U.S.: Nasdaq) | MarketWatch\n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\r\n\r\n\r\n\r\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n\n\n\n \n\n \n\n\n\n\n\n\n\n\n \n\n\n \n \n \n \n \n \n \n\n\n\n\r\n\r\n
\r\n \r\n
\r\n\n\n
\n\n
\n \n

\n Turns out the U.S. stock market is one of the world’s least concentrated\n

\n \n \n\n
\n
\n\r\n\r\n
\r\n
\r\n \r\n
\r\n
\r\n
\n\n
\n
\r\n
\r\n \r\n \r\n
\r\n
\r\n
\r\n\r\n\r\n
\n\n\n \n \n\n
\n\r\n\r\n
\r\n\r\n\r\n
\r\n\r\n\r\n
\r\n\r\n\r\n\r\n\r\n\r\n
\r\n
\r\n \r\n
\r\n
\r\n
\r\n
\r\n
\r\n\r\n\r\n
\r\n\r\n\r\n\n\n\n
\n
\n
\n \n \n
\n
\n S&P 500 Movers\n
\n \n\n \n
\n\n
\n\n
\n \n
\n
\n \n \n\r\n\r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n
\n \n Dow\n 38,835.12\n \n -137.29\n \n -0.35%\n \n \n \n \n
\n \n S&P 500\n 5,067.19\n \n -10.99\n \n -0.22%\n \n \n \n \n
\n \n Nasdaq\n 15,955.43\n \n -79.87\n \n -0.50%\n \n \n \n \n
\n \n VIX\n 13.67\n \n 0.24\n \n 1.79%\n \n \n \n \n
\n \n Gold\n 2,041.60\n \n -2.50\n \n -0.12%\n \n \n \n \n
\n \n Oil\n 79.37\n \n 0.50\n \n 0.63%\n \n \n \n \n
\n
\n
\n
\n
\n
\n
\n\n
\n \n
\n Latest News\n All Times Eastern\n
\n \n \n
\n
\n
\n \n
\n \n \n
\n\n
\n
\n
\r\n
\r\n
\r\n
\r\n\r\n\r\n
\r\n\r\n\r\n\r\n\r\n
    \r\n
  1. \r\n \r\n Home\r\n \r\n \r\n
    2. \r\n
  2. \r\n \r\n Investing\r\n \r\n \r\n
    3. \r\n
  3. \r\n \r\n Quotes\r\n \r\n \r\n
    4. \r\n
  4. \r\n \r\n Stocks\r\n \r\n \r\n
    5. \r\n
  5. \r\n \r\n United States\r\n \r\n \r\n
    6. \r\n
  6. \r\n \r\n PYPD\r\n \r\n \r\n
    7. \r\n
  7. \r\n \r\n Overview\r\n \r\n \r\n
    8. \r\n
\r\n\r\n\r\n \r\n
\r\n
\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n \r\n
\r\n
\r\n
\r\n \r\n \r\n
\r\n
    \r\n
    \r\n \r\n |\r\n
    \r\n
    \r\n PYPD\r\n U.S.: Nasdaq\r\n
    \r\n \r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n     \r\n
    \r\n
    \r\n

    PolyPid Ltd.

    \r\n
    \r\n Watchlist \r\n\r\n
    \r\n \r\n \r\n
    \r\n
    \r\n NEW\r\n
    \r\n
    \r\n Set a price target alert\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n
    \r\n PYPDUS
    Open
    \r\n
    \r\n Last Updated: Feb 28, 2024 10:13 a.m. EST\r\n Real time quote\r\n
    \r\n
    \r\n

    \r\n $\r\n 6.00\r\n

    \r\n \r\n \r\n 0.52\r\n 9.59%\r\n \r\n
    \r\n
    \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
    Previous Close
    $5.48
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n \r\n \r\n
    \r\n
    \r\n
    \r\n \r\n \r\n
    \r\n Advanced Charting\r\n
    \r\n \r\n \r\n
    \r\n
    \r\n \r\n \r\n \r\n
    \r\n
    \r\n     \r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n \r\n
    \r\n Volume: 2.92K\r\n 65 Day Avg: 7.37K\r\n
    \r\n
    \r\n
    \r\n 40% vs Avg\r\n
    \r\n
    \r\n     \r\n\r\n\r\n \r\n
    \r\n 5.47\r\n Day Range\r\n 6.00\r\n
    \r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n     \r\n\r\n\r\n \r\n
    \r\n 3.57\r\n 52 Week Range\r\n 22.20\r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n     \r\n
    \r\n
    \r\n \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\n
    \n
    \n

    \n Partner Center\n

    \n
    \n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n
    \r\n\r\n\r\n
    \r\n

    \r\n Your Watchlists\r\n

    \r\n
    \r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n
    Customize MarketWatch
    \r\n

    Have Watchlists? Log in to see them here or sign up to get started.

    \r\n
    \r\n
    \r\n Create Account\r\n … or Log In\r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n
    \r\n
    \r\n \r\n \r\n
    \r\n
    \r\n \r\n
    \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
    \r\n
    Symbol
    \r\n Company\r\n     		\r\n
    Price
    \r\n Chg/Chg %\r\n
    \r\n \r\n
    \r\n (Go to Your Watchlist) \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n
    \r\n
    No Items in Watchlist
    \r\n

    There are currently no items in this Watchlist.

    \r\n
    \r\n
    \r\n Add Tickers\r\n
    \r\n
    \r\n
    \r\n\r\n
    \r\n
    \r\n
    \r\n
    No Saved Watchlists
    \r\n

    Create a list of the investments you want to track.

    \r\n
    \r\n
    \r\n Create Watchlist\r\n …or learn more\r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n
    \r\n
    Uh oh
    \r\n

    Something went wrong while loading Watchlist.

    \r\n
    \r\n
    \r\n Go to Watchlist\r\n
    \r\n
    \r\n
    \r\n\r\n    \r\n\r\n
    \r\n

    \r\n Recently Viewed Tickers\r\n

    \r\n
    \r\n\r\n
    \r\n
    \r\n
    \r\n

    No Recent Tickers

    \r\n

    Visit a quote page and your recently viewed tickers will be displayed here.

    \r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n \r\n
    \r\n    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n\n\n
    \n
    \n\n\n
    \n
    \n
    \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\r\n\r\n \r\n
    \r\n \r\n

    Overview

    \r\n \r\n
    \r\n
    \r\n
  • \r\n Overview\r\n
    • \r\n
  • \r\n Profile\r\n
    • \r\n
  • \r\n Charts\r\n
    • \r\n
  • \r\n Financials\r\n
    • \r\n
  • \r\n Historical Quotes\r\n
    • \r\n
  • \r\n Analyst Estimates\r\n
    • \r\n
  • \r\n Options\r\n
    • \r\n\r\n
  • Premium Tools
    • \r\n\r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n\n\n
    \n

    \n PYPD Overview\n

    \n
    \n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\n
    \n
    \n

    \n Key Data\n

    \n
    \n
      \n
    • \n Open\n $5.98\n \n
      • \n
    • \n Day Range\n 5.47 - 6.00\n \n
      • \n
    • \n 52 Week Range\n 3.57 - 22.20\n \n
      • \n
    • \n Market Cap\n $9.49M\n \n
      • \n
    • \n Shares Outstanding\n 1.65M\n \n
      • \n
    • \n Public Float\n 1.39M\n \n
      • \n
    • \n Beta\n 0.99\n \n
      • \n
    • \n Rev. per Employee\n N/A\n \n
      • \n
    • \n P/E Ratio\n N/A\n \n
      • \n
    • \n EPS\n -$7.65\n \n
      • \n
    • \n Yield\n N/A\n \n
      • \n
    • \n Dividend\n N/A\n \n
      • \n
    • \n Ex-Dividend Date\n N/A\n \n
      • \n
    • \n Short Interest\n 7.28K\n 02/15/24\n
      • \n
    • \n % of Float Shorted\n 0.52%\n \n
      • \n
    • \n Average Volume\n 7.37K\n \n
      • \n
    \n
    \n
    \r\n
    \r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n

    \r\n Performance\r\n

    \r\n
    \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
    5 Day\r\n
      \r\n
    • 12.36%
      • \r\n
    • \r\n \r\n
      • \r\n
    \r\n
    1 Month\r\n
      \r\n
    • -4.76%
      • \r\n
    • \r\n \r\n
      • \r\n
    \r\n
    3 Month\r\n
      \r\n
    • 31.00%
      • \r\n
    • \r\n \r\n
      • \r\n
    \r\n
    YTD\r\n
      \r\n
    • 57.89%
      • \r\n
    • \r\n \r\n
      • \r\n
    \r\n
    1 Year\r\n
      \r\n
    • -69.70%
      • \r\n
    • \r\n \r\n
      • \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\n\n
    \n
    \n

    \n Analyst Ratings\n

    \n
    \n
    \n
      \n
    • Sell
      • \n
    • Under
      • \n
    • Hold
      • \n
    • Over
      • \n
    • Buy
      • \n
    \n Number of Ratings 3\n Full Ratings \n
    \n
    \n
    \r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n

    \r\n Recent News\r\n

    \r\n
    \r\n \r\n
    \r\n
      \r\n \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n\n\n \n \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n
    \n \n \n \n \n
    \n
    \n\n

    \n \n \n PolyPid downgraded to outperform from strong buy at Raymond James\n

    \n \n\n \n\n
    \n Sep. 6, 2022 at 7:09 a.m. ET\n\n by Tomi Kilgore\n \n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n
    \n \n \n \n \n
    \n
    \n\n

    \n \n \n PolyPid started at outperform with $23 stock price target at Raymond James\n

    \n \n\n \n\n
    \n Jul. 21, 2020 at 7:48 a.m. ET\n\n by Tomi Kilgore\n \n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n
    \n \n \n \n \n \n \n \n \n
    \n
    \n\n

    \n \n \n \n \n \n PolyPid sets IPO terms, could be valued at up to $279 million\n \n

    \n

    PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3.125 million shares in the IPO...

    \n\n \n\n
    \n Jun. 22, 2020 at 7:58 a.m. ET\n\n by Tomi Kilgore\n \n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n
    \n \n \n \n \n
    \n
    \n\n

    \n \n \n PolyPid sets IPO terms, to raise up to $53.1 mln\n

    \n \n\n \n\n
    \n Jun. 22, 2020 at 7:50 a.m. ET\n\n by Tomi Kilgore\n \n
    \n
    \n
    \n
    \n \n\n \n\n
    \n     \n \n \n \n
    \r\n
    \r\n\r\n\r\n\n\n \n \n
    \n
    \n
    \n
    \n
    \n
    \n

    No Headlines Available

    \n
    \n     \n \n \n \n
    \r\n
    \r\n     \r\n
    \r\n\r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n\r\n\r\n\r\n
    \r\n \r\n
    \r\n
      \r\n \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n\n\n \n \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?\n \n

    \n

    \n\n \n\n
    \n Feb. 19, 2024 at 12:00 p.m. ET\n\n \n on Zacks.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q4 2023 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q4 2023 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 15, 2024 at 12:07 a.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning\n \n

    \n

    \n\n \n\n
    \n Feb. 14, 2024 at 11:55 a.m. ET\n\n \n on TipRanks.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Earnings Scheduled For February 14, 2024\n \n

    \n

    \n\n \n\n
    \n Feb. 14, 2024 at 4:48 a.m. ET\n\n \n on Benzinga.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q3 2023 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q3 2023 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:52 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q2 2023 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q2 2023 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:52 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q1 2023 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q1 2023 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q4 2022 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q4 2022 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q3 2022 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q3 2022 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q2 2022 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q2 2022 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n PolyPid Ltd KOL Webinar Transcript\n \n

    \n

    PolyPid Ltd KOL Webinar Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n PolyPid Ltd To Discuss SHIELD I Interim Analysis Conference Call Transcript\n \n

    \n

    PolyPid Ltd To Discuss SHIELD I Interim Analysis Conference Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q1 2022 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q1 2022 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n PolyPid Ltd at Barclays Global Healthcare Conference Transcript\n \n

    \n

    PolyPid Ltd at Barclays Global Healthcare Conference Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q3 2021 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q3 2021 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q4 2021 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q4 2021 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q2 2021 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q2 2021 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n PolyPid Ltd at Raymond James Human Health Innovation Conference (Virtual) Transcript\n \n

    \n

    PolyPid Ltd at Raymond James Human Health Innovation Conference (Virtual) Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n Q1 2021 PolyPid Ltd Earnings Call Transcript\n \n

    \n

    Q1 2021 PolyPid Ltd Earnings Call Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n\r\n\r\n\r\n\n\n
    \n \n
    \n\n

    \n \n \n \n \n \n PolyPid Ltd at Barclays Global Healthcare Conference (Virtual) Transcript\n \n

    \n

    PolyPid Ltd at Barclays Global Healthcare Conference (Virtual) Transcript

    \n\n \n\n
    \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
    \n
    \n
    \n
    \n \n\n \n\n
    \n     \n \n \n \n
    \r\n
    \r\n\r\n\r\n\n\n \n \n
    \n
    \n
    \n
    \n
    \n
    \n

    No Headlines Available

    \n
    \n     \n \n \n \n
    \r\n
    \r\n     \r\n
    \r\n\n
    \n
    \n

    \n PolyPid Ltd.\n

    \n
    \n\n

    PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

    \n
    \n \r\n \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\n\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \n\n
    \n\n
    \n
    \n
    \n
    \n
    \n
    \n

    \n Advertisement\n

    \n
    \n
    \n
    \n
    \n\n
    \n
    \n
    \n

    \n Advertisement\n

    \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n\n
    \n\n\n
    \n\r\n\r\n\r\n\r\n \r\n\r\n
    \n\n\n
    \n
    \n
    \n
    \n
    \n
    \n
    \n\n\n\n\n\n\n\n\n\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n \n\r\n\r\n\r\n\r\n \n \n\r\n \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n

    Trending Tickers

    \r\n
    Above average volume.
    \r\n
    \r\n \r\n
    \r\n Access Premium Tools\r\n
    \r\n\r\n\r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n \n \n\r\n\r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n \r\n \r\n \r\n \r\n
    \r\n \r\n
    \r\n
    \r\n Advanced Search\r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n
    \r\n
    \r\n
    \r\n

    \r\n Search Results\r\n

    \r\n
    \r\n
    \r\n
    \r\n\r\n
    \r\n
    \r\n\n\n
    \n
    \n

    Symbols

    \n
    Loading...
    \n \n \n \n
    \n
    \n
    \n \n \n\n\n
    \n
    \n

    Private Companies

    \n
    Loading...
    \n \n \n \n
    \n
    \n
    \n\r\n
    \r\n

    \r\n Recently Viewed Tickers\r\n

    \r\n
    \r\n\r\n
    \r\n
    \r\n
    \r\n

    No Recent Tickers

    \r\n

    Visit a quote page and your recently viewed tickers will be displayed here.

    \r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n \r\n
    \r\n    \r\n
    \r\n
    \r\n\r\n\r\n\r\n
    \r\n \r\n
    \r\n
      \r\n \r\n \r\n \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n\r\n\r\n
    \r\n
    \r\n     \r\n
    \r\n
    \r\n
    \r\n\r\n
    \r\n
    \r\n
    \r\n\n
    \n

    Authors

    \n
    \n
    \n\n\n\n\n\n
    \n

    Sections

    \n
    \n
    \n\n\n\n\n\n
    \n

    Columns

    \n
    \n
    \n\n\n\n\n
    \r\n
    \r\n
    \r\n\r\n
    \r\n\r\n
    \r\n
    \r\n\n
    \r\n
    \r\n
    \r\n
    \r\n \r\n
    \r\n

    \r\n Video Center\r\n

    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n \n \n \n \n \n
    \n
    \n
    \n
    \n \n
    \n

    \n Time to Upgrade!\n

    \n
    \n
    \n
    \n
    \n

    This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

    \n
    \n
    \n Chrome\n Safari\n Firefox\n Edge\n
    \n
    \n
    \n
    \n
    \n \n \n \n\n \n \n \n\n\n", + "page_last_modified": "" + }, + { + "page_name": "PolyPid Announces Private Placement for $16 Million in Gross Proceeds ...", + "page_url": "https://investors.polypid.com/news-releases/news-release-details/polypid-announces-private-placement-16-million-gross-proceeds", + "page_snippet": "Financing Led by Leading U.S. Life Sciences-focused Investors PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (\u201cPolyPid\u201d or the \u201cCompany\u201d), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into ...Financing Led by Leading U.S. Life Sciences-focused Investors PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (\u201cPolyPid\u201d or the \u201cCompany\u201d), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities (Nasdaq: PYPD) (\u201cPolyPid\u201d or the \u201cCompany\u201d), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the \u201cPIPE\u201d) for \u00b7 $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (\u201cPolyPid\u201d or the \u201cCompany\u201d), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the \u201cPIPE\u201d) for The warrants expire upon the earlier of two years from the date of issuance and 10 trading days following PolyPid\u2019s announcement of the positive recommendation by Data Safety Monitoring Board regarding the Company\u2019s unblinded interim analysis in its SHIELD II Phase 3 trial of D-PLEX100 resulting in the stopping of the trial due to positive efficacy.", + "page_result": "\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n PolyPid Announces Private Placement for $16 Million in Gross Proceeds | Polypid\n \n\n\n\n\n\n \n\n\n \n \n \n
    \n \n Skip to main navigation\n \n
    \n \n
    \n \n
    \n
    \n
    \n
    \n
    \n \n
    \n     \n
    \n\n
    \n\n
    \n \n
    \n\n\n
    \n \n
    \n
    \n
    \n
    \n
    \n
    \n\n\n
    \n\n \n\n
    \n
    \n
    \n
    \n
    \n

    \n\n Press Releases\n

    \n
    \n
    \n
    \n
    \n
    \n\n\n\n
    \n
    \n
    \n\n
    \n
    \n
    \n \n \n \n
    \n
    \n
    \n \n \n \n
    \n

    < Back

    \n

    \n
    \n
    PolyPid Announces Private Placement for $16 Million in Gross Proceeds
    \n
    \n

    \n \n
    \n
    January 4, 2024 at 4:32 PM EST
    \n
    \n\n
    \n
    Financing Led by Leading U.S. Life Sciences-focused Investors
    \n

    PETACH TIKVA,\u00a0Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd.\u00a0(Nasdaq: PYPD) (\u201cPolyPid\u201d or the \u201cCompany\u201d), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the \u201cPIPE\u201d)\u00a0for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per share. The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors.

    \n

    Under the securities purchase agreement, the investors have agreed to purchase 3,371,312 of the Company\u2019s ordinary shares, no par value per share (the \u201cOrdinary Shares\u201d), or pre-funded warrants in lieu thereof, at a purchase price of $4.81 per share (or pre-funded warrant). The investors will also receive warrants to purchase up to 3,371,312 Ordinary Shares at an exercise price of\u00a0$5.50 per share. The warrants\u00a0expire upon the earlier of two years from the date of issuance and 10 trading days following\u00a0PolyPid\u2019s announcement\u00a0of the positive recommendation by Data Safety Monitoring Board regarding the Company\u2019s unblinded interim analysis in its SHIELD II Phase 3 trial of D-PLEX100 resulting in the stopping of the trial due to positive efficacy. Exercise of the warrants in full would result in an additional $18.5 million in gross proceeds to the Company.

    \n

    The PIPE is expected to close on January 9, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the sale of the securities for its ongoing SHIELD II phase 3 clinical trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, working capital and general corporate purposes.

    \n

    JMP Securities, A Citizens Company, is acting as exclusive placement agent in the offering.

    \n

    The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the PIPE investors, the Company has agreed to file within 30 calendar days of closing one or more registration statements with the Securities and Exchange Commission (the \"SEC\") covering the resale of the Ordinary Shares and Ordinary Shares issuable upon exercise of the warrants and pre-funded warrants.

    \n

    This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

    \n

    About D-PLEX100

    \n

    D-PLEX100,\u00a0PolyPid\u2019s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (SSIs). Following the administration of D-PLEX100\u00a0into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100\u00a0received\u00a0Breakthrough Therapy\u00a0Designation\u00a0from the\u00a0U.S.\u00a0Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100\u00a0 is currently in Phase 3 SHIELD II\u00a0trial for the prevention of surgical site infections in patients undergoing open abdominal colorectal surgery with large incisions.

    \n

    About\u00a0PolyPid

    \n

    PolyPid Ltd.\u00a0(Nasdaq:\u00a0PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid\u2019s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid\u2019s lead product candidate D-PLEX100\u00a0is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

    \n

    For additional Company information, please visit\u00a0http://www.polypid.com\u00a0and follow us on\u00a0Twitter\u00a0and\u00a0LinkedIn.

    \n

    Forward-looking Statements

    \n

    This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the gross proceeds received from the PIPE, intended use of proceeds from the PIPE, the anticipated closing date for the PIPE, and the anticipated gross proceeds from the exercise of warrants issued in the PIPE if such warrants are exercised in full. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company\u2019s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company\u2019s Annual Report on Form 20-F filed on\u00a0March 31, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

    \n

    References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.\u00a0PolyPid\u00a0is not responsible for the contents of third-party websites.

    \n

    Contacts:
    PolyPid Ltd.\u00a0
    Ori Warshavsky
    COO \u2013 US
    908-858-5995
    IR@Polypid.com

    \n

    Investors:
    Brian Ritchie
    LifeSci Advisors
    212-915-2578
    britchie@lifesciadvisors.com


    \"Primary

    \n

    \nSource: PolyPid Ltd.

    \n \n
    \n\n
    \n\n
    \n\n
    \n\n
    \n\n
    \n
    \n
    \n \n\n\n\n
    \n\n
    \n
    \n
    \n
    \n\n
    \n
    \n
    \n
    \n \n\n\n\n
    \n\n
    \n
    \n
    \n\n
    \n
    \n \n \n \n
    \n
    \n
    \n
    \n
    \n
    \"\"
    \n\n
    \n

    Technology

    \n\n

    PolyPid\u2019s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

    \nRead More >
    \n
    \n\n
    \n
    \"D-PLEX100\"
    \n\n
    \n

    D-PLEX100

    \n\n

    Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

    \nRead More >
    \n
    \n\n
    \n
    \"D-PLEX1000\"
    \n\n
    \n

    D-PLEX1000

    \n\n

    Comprised of antibiotic eluting \u00df tri-calcium phosphate (\u00dfTCP) granules, designed for bone related infections applications.

    \nRead More >
    \n
    \n
    \n
    \n
    \n
    \n \n
    \n \n
    \n\n
    \n\n\n\n
    \n\n \n \n \n\n\n\n \n \n\n", + "page_last_modified": " Wed, 28 Feb 2024 15:17:19 GMT" + }, + { + "page_name": "PYPD Stock Price | PolyPid Ltd. Stock Quote (U.S.: Nasdaq) | ...", + "page_url": "https://www.marketwatch.com/investing/stock/pypd", + "page_snippet": "PYPD | Complete PolyPid Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3.125 million shares in the IPO... PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. Above average volume.", + "page_result": "\n\n\n\n\n\n PYPD Stock Price | PolyPid Ltd. Stock Quote (U.S.: Nasdaq) | MarketWatch\n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\r\n\r\n\r\n\r\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n\n\n\n \n\n \n\n\n\n\n\n\n\n\n \n\n\n \n \n \n \n \n \n \n\n\n\n\r\n\r\n
    \r\n \r\n
    \r\n\n\n
    \n\n
    \n \n

    \n Turns out the U.S. stock market is one of the world’s least concentrated\n

    \n \n     \n\n
    \n
    \n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \n\n
    \n
    \r\n
    \r\n \r\n \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \n\n\n \n \n\n
    \n\r\n\r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\r\n\r\n\r\n
    \r\n
    \r\n \r\n
    \r\n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\n\n\n
    \n
    \n
    \n \n \n
    \n
    \n S&P 500 Movers\n
    \n \n\n \n
    \n\n
    \n\n
    \n \n
    \n
    \n \n \n\r\n\r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n \n \n \n \n \n \n \r\n \n
    \n \n Dow\n 38,835.12\n \n -137.29\n \n -0.35%\n \n \n \n \n
    \n \n S&P 500\n 5,067.19\n \n -10.99\n \n -0.22%\n \n \n \n \n
    \n \n Nasdaq\n 15,955.43\n \n -79.87\n \n -0.50%\n \n \n \n \n
    \n \n VIX\n 13.67\n \n 0.24\n \n 1.79%\n \n \n \n \n
    \n \n Gold\n 2,041.60\n \n -2.50\n \n -0.12%\n \n \n \n \n
    \n \n Oil\n 79.37\n \n 0.50\n \n 0.63%\n \n \n \n \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n\n
    \n \n
    \n Latest News\n All Times Eastern\n
    \n \n \n
    \n
    \n
    \n \n
    \n     \n \n
    \n\n
    \n
    \n
    \r\n
    \r\n
    \r\n
    \r\n\r\n\r\n
    \r\n\r\n\r\n\r\n\r\n
      \r\n
    1. \r\n \r\n Home\r\n \r\n \r\n
      2. \r\n
    2. \r\n \r\n Investing\r\n \r\n \r\n
      3. \r\n
    3. \r\n \r\n Quotes\r\n \r\n \r\n
      4. \r\n
    4. \r\n \r\n Stocks\r\n \r\n \r\n
      5. \r\n
    5. \r\n \r\n United States\r\n \r\n \r\n
      6. \r\n
    6. \r\n \r\n PYPD\r\n \r\n \r\n
      7. \r\n
    7. \r\n \r\n Overview\r\n \r\n \r\n
      8. \r\n
    \r\n\r\n\r\n \r\n
    \r\n
    \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n \r\n
    \r\n
    \r\n
    \r\n \r\n \r\n
    \r\n
      \r\n
      \r\n \r\n |\r\n
      \r\n
      \r\n PYPD\r\n U.S.: Nasdaq\r\n
      \r\n \r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n       \r\n
      \r\n
      \r\n

      PolyPid Ltd.

      \r\n
      \r\n Watchlist \r\n\r\n
      \r\n \r\n \r\n
      \r\n
      \r\n NEW\r\n
      \r\n
      \r\n Set a price target alert\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n\r\n\r\n
      \r\n PYPDUS
      Open
      \r\n
      \r\n Last Updated: Feb 28, 2024 10:13 a.m. EST\r\n Real time quote\r\n
      \r\n
      \r\n

      \r\n $\r\n 6.00\r\n

      \r\n \r\n \r\n 0.52\r\n 9.59%\r\n \r\n
      \r\n
      \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
      Previous Close
      $5.48
      \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n\r\n\r\n \r\n \r\n
      \r\n
      \r\n
      \r\n \r\n \r\n
      \r\n Advanced Charting\r\n
      \r\n \r\n \r\n
      \r\n
      \r\n \r\n \r\n \r\n
      \r\n
      \r\n       \r\n
      \r\n
      \r\n\r\n\r\n\r\n\r\n \r\n
      \r\n Volume: 2.92K\r\n 65 Day Avg: 7.37K\r\n
      \r\n
      \r\n
      \r\n 40% vs Avg\r\n
      \r\n
      \r\n       \r\n\r\n\r\n \r\n
      \r\n 5.47\r\n Day Range\r\n 6.00\r\n
      \r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n       \r\n\r\n\r\n \r\n
      \r\n 3.57\r\n 52 Week Range\r\n 22.20\r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n       \r\n
      \r\n
      \r\n \r\n
      \r\n\r\n\r\n
      \r\n\r\n\r\n\r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\n
      \n
      \n

      \n Partner Center\n

      \n
      \n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\r\n\r\n\r\n\r\n
      \r\n\r\n\r\n
      \r\n

      \r\n Your Watchlists\r\n

      \r\n
      \r\n\r\n\r\n\r\n\r\n
      \r\n
      \r\n
      Customize MarketWatch
      \r\n

      Have Watchlists? Log in to see them here or sign up to get started.

      \r\n
      \r\n
      \r\n Create Account\r\n … or Log In\r\n
      \r\n
      \r\n\r\n\r\n\r\n\r\n
      \r\n
      \r\n
      \r\n
      \r\n \r\n \r\n
      \r\n
      \r\n \r\n
      \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
      \r\n
      Symbol
      \r\n Company\r\n       		\r\n
      Price
      \r\n Chg/Chg %\r\n
      \r\n \r\n
      \r\n (Go to Your Watchlist) \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n
      \r\n
      No Items in Watchlist
      \r\n

      There are currently no items in this Watchlist.

      \r\n
      \r\n
      \r\n Add Tickers\r\n
      \r\n
      \r\n
      \r\n\r\n
      \r\n
      \r\n
      \r\n
      No Saved Watchlists
      \r\n

      Create a list of the investments you want to track.

      \r\n
      \r\n
      \r\n Create Watchlist\r\n …or learn more\r\n
      \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n
      \r\n
      Uh oh
      \r\n

      Something went wrong while loading Watchlist.

      \r\n
      \r\n
      \r\n Go to Watchlist\r\n
      \r\n
      \r\n
      \r\n\r\n      \r\n\r\n
      \r\n

      \r\n Recently Viewed Tickers\r\n

      \r\n
      \r\n\r\n
      \r\n
      \r\n
      \r\n

      No Recent Tickers

      \r\n

      Visit a quote page and your recently viewed tickers will be displayed here.

      \r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n \r\n
      \r\n      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n\n\n
      \n
      \n\n\n
      \n
      \n
      \r\n
      \r\n\r\n\r\n
      \r\n\r\n\r\n\r\n\r\n \r\n
      \r\n \r\n

      Overview

      \r\n \r\n
      \r\n
      \r\n
    • \r\n Overview\r\n
      • \r\n
    • \r\n Profile\r\n
      • \r\n
    • \r\n Charts\r\n
      • \r\n
    • \r\n Financials\r\n
      • \r\n
    • \r\n Historical Quotes\r\n
      • \r\n
    • \r\n Analyst Estimates\r\n
      • \r\n
    • \r\n Options\r\n
      • \r\n\r\n
    • Premium Tools
      • \r\n\r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n\n\n
      \n

      \n PYPD Overview\n

      \n
      \n
      \r\n\r\n\r\n
      \r\n\r\n\r\n\n
      \n
      \n

      \n Key Data\n

      \n
      \n
        \n
      • \n Open\n $5.98\n \n
        • \n
      • \n Day Range\n 5.47 - 6.00\n \n
        • \n
      • \n 52 Week Range\n 3.57 - 22.20\n \n
        • \n
      • \n Market Cap\n $9.49M\n \n
        • \n
      • \n Shares Outstanding\n 1.65M\n \n
        • \n
      • \n Public Float\n 1.39M\n \n
        • \n
      • \n Beta\n 0.99\n \n
        • \n
      • \n Rev. per Employee\n N/A\n \n
        • \n
      • \n P/E Ratio\n N/A\n \n
        • \n
      • \n EPS\n -$7.65\n \n
        • \n
      • \n Yield\n N/A\n \n
        • \n
      • \n Dividend\n N/A\n \n
        • \n
      • \n Ex-Dividend Date\n N/A\n \n
        • \n
      • \n Short Interest\n 7.28K\n 02/15/24\n
        • \n
      • \n % of Float Shorted\n 0.52%\n \n
        • \n
      • \n Average Volume\n 7.37K\n \n
        • \n
      \n
      \n
      \r\n
      \r\n\r\n\r\n\r\n\r\n
      \r\n
      \r\n

      \r\n Performance\r\n

      \r\n
      \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
      5 Day\r\n
        \r\n
      • 12.36%
        • \r\n
      • \r\n \r\n
        • \r\n
      \r\n
      1 Month\r\n
        \r\n
      • -4.76%
        • \r\n
      • \r\n \r\n
        • \r\n
      \r\n
      3 Month\r\n
        \r\n
      • 31.00%
        • \r\n
      • \r\n \r\n
        • \r\n
      \r\n
      YTD\r\n
        \r\n
      • 57.89%
        • \r\n
      • \r\n \r\n
        • \r\n
      \r\n
      1 Year\r\n
        \r\n
      • -69.70%
        • \r\n
      • \r\n \r\n
        • \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n\r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\n\n
      \n
      \n

      \n Analyst Ratings\n

      \n
      \n
      \n
        \n
      • Sell
        • \n
      • Under
        • \n
      • Hold
        • \n
      • Over
        • \n
      • Buy
        • \n
      \n Number of Ratings 3\n Full Ratings \n
      \n
      \n
      \r\n
      \r\n
      \r\n\r\n\r\n\r\n\r\n\r\n
      \r\n
      \r\n

      \r\n Recent News\r\n

      \r\n
      \r\n \r\n
      \r\n
        \r\n \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n\n\n \n \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n
      \n \n \n \n \n
      \n
      \n\n

      \n \n \n PolyPid downgraded to outperform from strong buy at Raymond James\n

      \n \n\n \n\n
      \n Sep. 6, 2022 at 7:09 a.m. ET\n\n by Tomi Kilgore\n \n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n
      \n \n \n \n \n
      \n
      \n\n

      \n \n \n PolyPid started at outperform with $23 stock price target at Raymond James\n

      \n \n\n \n\n
      \n Jul. 21, 2020 at 7:48 a.m. ET\n\n by Tomi Kilgore\n \n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n
      \n \n \n \n \n \n \n \n \n
      \n
      \n\n

      \n \n \n \n \n \n PolyPid sets IPO terms, could be valued at up to $279 million\n \n

      \n

      PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3.125 million shares in the IPO...

      \n\n \n\n
      \n Jun. 22, 2020 at 7:58 a.m. ET\n\n by Tomi Kilgore\n \n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n
      \n \n \n \n \n
      \n
      \n\n

      \n \n \n PolyPid sets IPO terms, to raise up to $53.1 mln\n

      \n \n\n \n\n
      \n Jun. 22, 2020 at 7:50 a.m. ET\n\n by Tomi Kilgore\n \n
      \n
      \n
      \n
      \n \n\n \n\n
      \n       \n \n \n \n
      \r\n
      \r\n\r\n\r\n\n\n \n \n
      \n
      \n
      \n
      \n
      \n
      \n

      No Headlines Available

      \n
      \n       \n \n \n \n
      \r\n
      \r\n       \r\n
      \r\n\r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n\r\n\r\n\r\n
      \r\n \r\n
      \r\n
        \r\n \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n\n\n \n \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?\n \n

      \n

      \n\n \n\n
      \n Feb. 19, 2024 at 12:00 p.m. ET\n\n \n on Zacks.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q4 2023 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q4 2023 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 15, 2024 at 12:07 a.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning\n \n

      \n

      \n\n \n\n
      \n Feb. 14, 2024 at 11:55 a.m. ET\n\n \n on TipRanks.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Earnings Scheduled For February 14, 2024\n \n

      \n

      \n\n \n\n
      \n Feb. 14, 2024 at 4:48 a.m. ET\n\n \n on Benzinga.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q3 2023 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q3 2023 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:52 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q2 2023 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q2 2023 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:52 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q1 2023 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q1 2023 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q4 2022 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q4 2022 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q3 2022 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q3 2022 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q2 2022 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q2 2022 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n PolyPid Ltd KOL Webinar Transcript\n \n

      \n

      PolyPid Ltd KOL Webinar Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n PolyPid Ltd To Discuss SHIELD I Interim Analysis Conference Call Transcript\n \n

      \n

      PolyPid Ltd To Discuss SHIELD I Interim Analysis Conference Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q1 2022 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q1 2022 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n PolyPid Ltd at Barclays Global Healthcare Conference Transcript\n \n

      \n

      PolyPid Ltd at Barclays Global Healthcare Conference Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q3 2021 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q3 2021 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q4 2021 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q4 2021 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q2 2021 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q2 2021 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n PolyPid Ltd at Raymond James Human Health Innovation Conference (Virtual) Transcript\n \n

      \n

      PolyPid Ltd at Raymond James Human Health Innovation Conference (Virtual) Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n Q1 2021 PolyPid Ltd Earnings Call Transcript\n \n

      \n

      Q1 2021 PolyPid Ltd Earnings Call Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n\r\n\r\n\r\n\n\n
      \n \n
      \n\n

      \n \n \n \n \n \n PolyPid Ltd at Barclays Global Healthcare Conference (Virtual) Transcript\n \n

      \n

      PolyPid Ltd at Barclays Global Healthcare Conference (Virtual) Transcript

      \n\n \n\n
      \n Feb. 8, 2024 at 2:51 p.m. ET\n\n \n on GuruFocus.com\n
      \n
      \n
      \n
      \n \n\n \n\n
      \n       \n \n \n \n
      \r\n
      \r\n\r\n\r\n\n\n \n \n
      \n
      \n
      \n
      \n
      \n
      \n

      No Headlines Available

      \n
      \n       \n \n \n \n
      \r\n
      \r\n       \r\n
      \r\n\n
      \n
      \n

      \n PolyPid Ltd.\n

      \n
      \n\n

      PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

      \n
      \n \r\n \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n\r\n\r\n\n\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n\r\n\r\n\r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \n\n
      \n\n
      \n
      \n
      \n
      \n
      \n
      \n

      \n Advertisement\n

      \n
      \n
      \n
      \n
      \n\n
      \n
      \n
      \n

      \n Advertisement\n

      \n
      \n
      \n
      \n
      \n
      \n
      \n
      \n\n
      \n\n\n
      \n\r\n\r\n\r\n\r\n \r\n\r\n
      \n\n\n
      \n
      \n
      \n
      \n
      \n
      \n
      \n\n\n\n\n\n\n\n\n\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n \n\r\n\r\n\r\n\r\n \n \n\r\n \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n

      Trending Tickers

      \r\n
      Above average volume.
      \r\n
      \r\n \r\n
      \r\n Access Premium Tools\r\n
      \r\n\r\n\r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n \n \n\r\n\r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n \r\n \r\n \r\n \r\n
      \r\n \r\n
      \r\n
      \r\n Advanced Search\r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n
      \r\n
      \r\n
      \r\n

      \r\n Search Results\r\n

      \r\n
      \r\n
      \r\n
      \r\n\r\n
      \r\n
      \r\n\n\n
      \n
      \n

      Symbols

      \n
      Loading...
      \n \n \n \n
      \n
      \n
      \n \n \n\n\n
      \n
      \n

      Private Companies

      \n
      Loading...
      \n \n \n \n
      \n
      \n
      \n\r\n
      \r\n

      \r\n Recently Viewed Tickers\r\n

      \r\n
      \r\n\r\n
      \r\n
      \r\n
      \r\n

      No Recent Tickers

      \r\n

      Visit a quote page and your recently viewed tickers will be displayed here.

      \r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n \r\n
      \r\n      \r\n
      \r\n
      \r\n\r\n\r\n\r\n
      \r\n \r\n
      \r\n
        \r\n \r\n \r\n \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n\r\n\r\n
      \r\n
      \r\n       \r\n
      \r\n
      \r\n
      \r\n\r\n
      \r\n
      \r\n
      \r\n\n
      \n

      Authors

      \n
      \n
      \n\n\n\n\n\n
      \n

      Sections

      \n
      \n
      \n\n\n\n\n\n
      \n

      Columns

      \n
      \n
      \n\n\n\n\n
      \r\n
      \r\n
      \r\n\r\n
      \r\n\r\n
      \r\n
      \r\n\n
      \r\n
      \r\n
      \r\n
      \r\n \r\n
      \r\n

      \r\n Video Center\r\n

      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n \r\n
      \r\n
      \r\n
      \r\n
      \r\n \n \n \n \n \n
      \n
      \n
      \n
      \n \n
      \n

      \n Time to Upgrade!\n

      \n
      \n
      \n
      \n
      \n

      This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

      \n
      \n
      \n Chrome\n Safari\n Firefox\n Edge\n
      \n
      \n
      \n
      \n
      \n \n \n \n\n \n \n \n\n\n", + "page_last_modified": "" + }, + { + "page_name": "PolyPid Ltd. (PYPD) Stock Price, News, Quote & History - Yahoo Finance", + "page_url": "https://finance.yahoo.com/quote/PYPD/", + "page_snippet": "Find the latest PolyPid Ltd. (PYPD) stock quote, history, news and other vital information to help you with your stock trading and investing.PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you all for participating in PolyPid\u2019s third quarter 2023 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid\u2019s Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer of PolyPid. Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of Good Manufacturing Practice Audit of Company\u2019s Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you all for participating in PolyPid\u2019s third quarter 2023 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid\u2019s Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer of PolyPid. [\u2026]", + "page_result": "PolyPid Ltd. (PYPD) Stock Price, News, Quote & History - Yahoo Finance
      \n Advertisement\n
      U.S. markets close in 5 hours 43 minutes

      PolyPid Ltd. (PYPD)

      NasdaqCM - NasdaqCM Real Time Price. Currency in USD
      Follow
      Visitors trend2W10W9M
      6.00+0.51 (+9.29%)
      As of 10:13AM EST. Market open.
      Full screen
      Trade prices are not sourced from all markets
      Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
      Chart Events
      \"\"
      Bullishpattern detected
      \"Fast

      Fast Stochastic

      Performance Outlook
      Previous Close5.49
      Open5.98
      Bid5.37 x 900
      Ask6.59 x 4000
      Day's Range5.98 - 6.00
      52 Week Range3.57 - 22.20
      Volume4,165
      Avg. Volume7,754
      Market Cap28.784M
      Beta (5Y Monthly)1.48
      PE Ratio (TTM)N/A
      EPS (TTM)-16.99
      Earnings DateMay 08, 2024 - May 13, 2024
      Forward Dividend & YieldN/A (N/A)
      Ex-Dividend DateN/A
      1y Target Est12.33
      Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
      Fair Value
      \"\"
      XX.XX
      Overvalued

      Subscribe to Yahoo Finance Plus to view Fair Value for PYPD

      View details
      Research that delivers an independent perspective, consistent methodology and actionable insight
      Related Research
      \"\"
      • PolyPid Ltd.
        Daily \u2013 Vickers Top Insider Picks for 02/27/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
        Rating
        Fair Value
        Economic Moat
        yesterdayArgus Research
      View more
      \n Advertisement\n
      \n Advertisement\n
      \n Advertisement\n
      \n
      \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "page_last_modified": "" + }, + { + "page_name": "PolyPid - Optimized Therapeutics", + "page_url": "https://www.polypid.com/", + "page_snippet": "ABOUT US We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the ...ABOUT US We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023 PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX\u2081\u2080\u2080 and PLEX Technology Platform", + "page_result": "\n\n\n\n\n\n \n PolyPid - Optimized Therapeutics\n \n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\n\n\t\t\n\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \t\t\n\t\t \n \n \n \n\n\n\n\n
      \n
      \n
      \n
      \n
      \n \n
      \n       \n
      \n\n
      \n\n
      \n \n
      \n\n\n \n
      \n
      \n
      \n
      \n
      \n\n\n\n
      \n\n
      \n\n
      \n \n\t\t\n\t\t
      \n\n\t\t\t\n\t\t\t\n\t\t\t
      \n\t\t\t\t \t\t\t\t \n\t\t\t
      \n\t\t\t\t\t\"\"\n\n\t\t\t\t\t
      \n
      \u00a0
      \n\n\t\t\t\t\t
      \n
      OPTIMIZED
      THERAPEUTICS
      \n\n\t\t\t\t\t
      \n
      Local medications to transform the surgical practice.
      \n\n\t\t\t\t\t
      \nLOCALLY PRESENTED
      \n\n\t\t\t\t\t\"\"\n\n\t\t\t\t\t\"\"\n\n\t\t\t\t\t\"\"\n\n\t\t\t\t\t\"\"\n\n\n\t\t\t\t
      \n\n\t\t\t
      \n\t\t\t\n\n\t\t\t \n\t\t
      \n\t\t\n\n\t\t\n\n
      \n\n
      \n
      Revolutionizing medication practice by a platform of localized,\r\ncontrolled and prolonged drug release solutions.
      \n
      \n\n
      \n\n\n\n
      \n\n
      \n\n
      \n Latest News\n
      \n
      \n
      \n\n \n
      \n\n\n \n\n
      \n\n
      \n \n All News\n \n
      \n\n
      \n
      \n
      \n\n\n\n\n\n
      \n\n
      \n\n
      \n\n \n
      \n\n
      \n
      \n






      \n Play
      \n
      \n\n \n
      \n
      \n
      \n
      \n \n
      \n
      \n \n
      \n\n
      \n
      \n
      \n\n \n

      ABOUT US

      \n

      We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes.

      \n

      Our PLEX (Polymer-Lipid Encapsulation matriX) technology\u00a0is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications.

      \n

      Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner.\u00a0 This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer.

      \n

      Read more >

      \n

      TECHNOLOGY

      \n
        \n
      • PLEX (Polymer-Lipid\u00a0Encapsulation matriX) platform is made of alternating layers of polymers and lipids that entrap a therapeutic drug to form a protected reservoir.
        • \n
      • PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months, a rare combination of attributes.
        • \n
      • The PLEX platform is able to accommodate a large variety of different molecules, regardless of size or physical characteristics:
        • \n
      \n
      \n
      \n


      VIDEO:
      PLEX DRUG
      DELIVERY PLATFORM

      \n Play
      \n
      \n\n \n
      \n
      \n
      \n
      \n \n
      \n
      \n \n
      \n\n
      \n
      \n
      \n\n \n

      \"\"

      \n
      SMALL MOLECULES
      \n

      \"\"

      \n
      PROTEINS
      \n

      \"\"

      \n
      PEPTIDES
      \n

      \"\"

      \n
      NUCLEIC ACIDS
      \n

      \"Pipeline-img\"

      \n

      LEAD DEVELOPMENT\u00a0 PROGRAM

      \n

      Our lead development program is focused on providing a local solution for surgeons to prevent surgical site infection.

      \n

      Our novel\u00a0 D-PLEX100 product candidate delivers a broad-spectrum antibiotic, doxycycline, generating high local concentration over four weeks with minimal systemic exposure:

      \n
        \n
      • Prevents surgical site infections (both gram negative and positive)
        • \n
      • High local concentration over prolong period addresses resistant bacteria
        • \n
      • Local delivery eliminates systemic safety concerns
        • \n
      • Improves patient outcomes from infection related complications
        • \n
      \n

      Our product candidates are designed to release antibiotics locally, in a controlled manner, over extended periods of time, in a variety of medical conditions.

      \n

      PARTNERSHIP OPPORTUNITIES

      \n

      PolyPid is actively evaluating partnership and licensing opportunities across our platform technology and our product candidates.

      \n

      Our PLEX platform as a local drug delivery vehicle is designed to optimize drugs\u2019 local therapeutic effect and clinical outcome in patients.

      \n

      Our opportunities are focused around:

      \n
        \n
      • Partnerships to enhance the commercial introduction of our lead development program to surgeons and the hospital surgical suite for the prevention of surgical site infections
        • \n
      • License our technology delivery to improve proprietary product delivery for partners
        • \n
      • Licensing our pipeline assets to partners to improve patient outcomes
        • \n
      \n

      \"\" \"\" \"\"

      \n

       

      \n

       

      \n

       

      \n

       

      \n

      Read more >

      \n

      \"PARTNERSHIP

      \n
      \n
      \n\n \n
      \n \n
      \n\n
      \n \n\n\n \n
      \n
      \n
      \n\n \n
      \n
      \n \"\"\n
      \n
      \n

      About

      \n

      We are developing, manufacturing and intend to\u00a0 commercialize our products portfolio based on our proprietary PLEX technology targeting local prolonged delivery with single applications in the acute care surgical setting to improve patient outcomes.

      \n Read More >\n
      \n
      \n\n \n
      \n
      \n \"\"\n
      \n
      \n

      Partner with us

      \n

      PLEX platform will provide companies targeted, local\u00a0 delivery vehicle aimed to optimize their drugs\u2019 therapeutic payload and improve patient outcomes.

      \n Read More >\n
      \n
      \n\n \n
      \n
      \n
      \n\n\n\n \n\n\n\n\n\n\n", + "page_last_modified": "" + } + ] +} \ No newline at end of file